Clinical Trial Page

Summary
EudraCT Number:2021-004931-10
Sponsor's Protocol Code Number:R3918-PNH-2050
National Competent Authority:Spain - AEMPS
Clinical Trial Type:EEA CTA
Trial Status:Ongoing
Date on which this record was first entered in the EudraCT database:2023-01-10
Trial results
A. Protocol Information
A.1Member State ConcernedSpain - AEMPS
A.2EudraCT number2021-004931-10
A.3Full title of the trial
An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
Estudio abierto de extensión para evaluar la seguridad, tolerabilidad y eficacia a largo plazo del tratamiento combinado de pozelimab y cemdisirán en pacientes con hemoglobinuria paroxística nocturna
A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
A study to examine the long-term safety, tolerability, and effectiveness of Pozelimab and Cemdisiran combination therapy in adult patients with Paroxysmal Nocturnal Hemoglobinuria
Un estudio para examinar la seguridad, la tolerabilidad y la eficacia a largo plazo de la terapia combinada de pozelimab y cemdisiran en pacientes adultos con hemoglobinuria paroxística nocturna
A.3.2Name or abbreviated title of the trial where available
ACCESS-EXTENSION
ACCESO-EXTENSIÓN
A.4.1Sponsor's protocol code numberR3918-PNH-2050
A.7Trial is part of a Paediatric Investigation Plan No
A.8EMA Decision number of Paediatric Investigation Plan
B. Sponsor Information
B.Sponsor: 1
B.1.1Name of SponsorRegeneron Pharmaceuticals, Inc.
B.1.3.4CountryUnited States
B.3.1 and B.3.2Status of the sponsorCommercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1Name of organisation providing supportRegeneron Pharmaceuticals, Inc.
B.4.2CountryUnited States
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1Name of organisationRegeneron Pharmaceuticals, Inc.
B.5.2Functional name of contact pointClinical Trial Information
B.5.3 Address:
B.5.3.1Street Address777 Old Saw Mill River Road
B.5.3.2Town/ cityTarrytown
B.5.3.3Post code10591
B.5.3.4CountryUnited States
B.5.4Telephone number0034900834223
B.5.6E-mailRegistroEspanolDeEstudiosClinicos@Druginfo.com
D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3IMP RoleTest
D.2 Status of the IMP to be used in the clinical trial
D.2.1IMP to be used in the trial has a marketing authorisation No
D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
D.2.5.1Orphan drug designation number
D.3 Description of the IMP
D.3.1Product namePozelimab
D.3.2Product code REGN3918
D.3.4Pharmaceutical form Solution for injection
D.3.4.1Specific paediatric formulation No
D.3.7Routes of administration for this IMPSubcutaneous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8INN - Proposed INNPozelimab
D.3.9.2Current sponsor codeREGN3918
D.3.10 Strength
D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
D.3.10.2Concentration typeequal
D.3.10.3Concentration number200
D.3.11 The IMP contains an:
D.3.11.1Active substance of chemical origin No
D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
The IMP is a:
D.3.11.3Advanced Therapy IMP (ATIMP) No
D.3.11.3.1Somatic cell therapy medicinal product No
D.3.11.3.2Gene therapy medical product No
D.3.11.3.3Tissue Engineered Product No
D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
D.3.11.5Radiopharmaceutical medicinal product No
D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
D.3.11.7Plasma derived medicinal product No
D.3.11.8Extractive medicinal product No
D.3.11.9Recombinant medicinal product Yes
D.3.11.10Medicinal product containing genetically modified organisms No
D.3.11.11Herbal medicinal product No
D.3.11.12Homeopathic medicinal product No
D.3.11.13Another type of medicinal product No
D.IMP: 2
D.1.2 and D.1.3IMP RoleTest
D.2 Status of the IMP to be used in the clinical trial
D.2.1IMP to be used in the trial has a marketing authorisation No
D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
D.2.5.1Orphan drug designation number0000061148
D.3 Description of the IMP
D.3.1Product nameCemdisiran
D.3.2Product code ALN-CC5
D.3.4Pharmaceutical form Solution for injection
D.3.4.1Specific paediatric formulation No
D.3.7Routes of administration for this IMPSubcutaneous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8INN - Proposed INNCemdisiran
D.3.9.2Current sponsor codeALN-CC5
D.3.9.4EV Substance CodeSUB217110
D.3.10 Strength
D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
D.3.10.2Concentration typeequal
D.3.10.3Concentration number200
D.3.11 The IMP contains an:
D.3.11.1Active substance of chemical origin Yes
D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
The IMP is a:
D.3.11.3Advanced Therapy IMP (ATIMP) No
D.3.11.3.1Somatic cell therapy medicinal product No
D.3.11.3.2Gene therapy medical product No
D.3.11.3.3Tissue Engineered Product No
D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
D.3.11.5Radiopharmaceutical medicinal product No
D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
D.3.11.7Plasma derived medicinal product No
D.3.11.8Extractive medicinal product No
D.3.11.9Recombinant medicinal product No
D.3.11.10Medicinal product containing genetically modified organisms No
D.3.11.11Herbal medicinal product No
D.3.11.12Homeopathic medicinal product No
D.3.11.13Another type of medicinal product No
D.IMP: 3
D.1.2 and D.1.3IMP RoleTest
D.2 Status of the IMP to be used in the clinical trial
D.2.1IMP to be used in the trial has a marketing authorisation No
D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
D.2.5.1Orphan drug designation number
D.3 Description of the IMP
D.3.1Product namePozelimab
D.3.2Product code REGN3918
D.3.4Pharmaceutical form Solution for injection/infusion
D.3.4.1Specific paediatric formulation No
D.3.7Routes of administration for this IMPSubcutaneous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8INN - Proposed INNPozelimab
D.3.9.2Current sponsor codeREGN3918
D.3.10 Strength
D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
D.3.10.2Concentration typeequal
D.3.10.3Concentration number200
D.3.11 The IMP contains an:
D.3.11.1Active substance of chemical origin No
D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
The IMP is a:
D.3.11.3Advanced Therapy IMP (ATIMP) No
D.3.11.3.1Somatic cell therapy medicinal product No
D.3.11.3.2Gene therapy medical product No
D.3.11.3.3Tissue Engineered Product No
D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
D.3.11.5Radiopharmaceutical medicinal product No
D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
D.3.11.7Plasma derived medicinal product No
D.3.11.8Extractive medicinal product No
D.3.11.9Recombinant medicinal product Yes
D.3.11.10Medicinal product containing genetically modified organisms No
D.3.11.11Herbal medicinal product No
D.3.11.12Homeopathic medicinal product No
D.3.11.13Another type of medicinal product No
D.8 Information on Placebo
E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1Medical condition(s) being investigated
Paroxysmal nocturnal hemoglobinuria (PNH)
hemoglobinuria paroxística nocturna (HPN)
E.1.1.1Medical condition in easily understood language
Paroxysmal nocturnal hemoglobinuria (PNH)
hemoglobinuria paroxística nocturna (HPN)
E.1.1.2Therapeutic area Diseases [C] - Blood and lymphatic diseases [C15]
MedDRA Classification
E.1.2 Medical condition or disease under investigation
E.1.2Version 21.1
E.1.2Level LLT
E.1.2Classification code 10055629
E.1.2Term Paroxysmal nocturnal hemoglobinuria
E.1.2System Organ Class 100000004857
E.1.3Condition being studied is a rare disease Yes
E.2 Objective of the trial
E.2.1Main objective of the trial
The primary objective of the study is to describe the long-term safety, tolerability, and efficacy of pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria (PNH)
El objetivo principal del estudio es describir la seguridad, tolerabilidad y eficacia a largo plazo de la terapia combinada de pozelimab y cemdisiran en pacientes con hemoglobinuria paroxística nocturna (HPN).
E.2.2Secondary objectives of the trial
The secondary objectives of the study are to describe the long-term effect of the combination of pozelimab and cemdisiran on:
• Measures of intravascular hemolysis
• Transfusion parameters
• Hemoglobin levels
• Fatigue as assessed by a Patient Reported Outcome (PRO)
• Physical Function as assessed by a PRO
• Change in Global Health Status (GHS) as assessed by a PRO
• Complement activation
• Concentrations of total pozelimab in serum and cemdisiran and total
complement component 5 (C5) protein in plasma
• Immunogenicity of pozelimab & cemdisiran
El objetivo principal del estudio es definir la seguridad, tolerabilidad y eficacia a largo plazo del tratamiento combinado con pozelimab y cemdisiran:
• Indicadores de hemólisis intravascular
• Parámetros de transfusión
• Cantidad de hemoglobina
• Fatiga evaluada mediante resultados comunicados por el paciente (RCP)
• Función física evaluada mediante RCP
• Cambio en el estado de salud general (ESG) evaluado mediante RCP
• Activación del complemento
• Concentraciones totales de pozelimab en suero y cemdisiran y proteína total del componente 5 del complemento (C5) en plasma
• Inmunogenicidad del pozelimab y el cemdisiran
E.2.3Trial contains a sub-study Yes
E.2.3.1Full title, date and version of each sub-study and their related objectives
Future Biomedical Research
Patients who agree to participate in the future biomedical research (FBR) sub-study will be required to consent to this optional sub-study before samples are banked for FBR. The samples may be utilized for FBR that may or may not be directly related to the study, including being used as reference samples and assay development or validation. The results of these future biomedical research analyses will not be presented in the CSR.

Pharmacogenomic Analysis
Patients who agree to participate in the genomics sub-study will be required to consent to this optional sub-study before collection of the samples. The purpose of the pharmacogenomic analyses is to identify genomic associations with clinical or biomarker response to pozelimab and cemdisiran, other PNH clinical outcome measures and
possible AEs. In addition, associations between genomic variants and prognosis or progression of PNH as well as related complement-mediated diseases may also be studied. These data may be used or combined with data collected from other studies to identify and validate genomic markers related to the study drug, target pathway, or PNH and related diseases.
Investigación biomédica futura
Los pacientes que acepten participar en el subestudio de investigación biomédica futura (IBF) deberán dar su consentimiento para este subestudio opcional antes de que las muestras se almacenen para IBF. Las muestras se pueden utilizar para IBF que pueden o no estar directamente relacionadas con el estudio, incluido el uso como muestras de referencia y desarrollo o validación de ensayos. Los resultados de estos análisis de investigación biomédica futura no se presentarán en el CSR.
Análisis farmacogenómico
Los pacientes que acepten participar en el subestudio de genómica deberán dar su consentimiento para este subestudio opcional antes de la recolección de las muestras. El propósito de los análisis farmacogenómicos es identificar asociaciones genómicas con respuesta clínica o de biomarcadores a pozelimab y cemdisiran, otras medidas de resultados clínicos de HPN y posibles AA. Además, también se pueden estudiar las asociaciones entre las variantes genómicas y el pronóstico o la progresión de la HPN, así como las enfermedades relacionadas mediadas por el complemento. Estos datos pueden usarse o combinarse con datos recopilados de otros estudios para identificar y validar marcadores genómicos relacionados con el fármaco del estudio, la vía diana o la HPN y enfermedades relacionadas.
E.3Principal inclusion criteria
1. Patients with PNH who have completed, without permanent discontinuation, study treatment in at least 1 of the parent studies (R3918-PNH-2021[NCT05133531] and/or R3918-PNH-2022 [NCT05131204]) including the transition period, if applicable.

Other protocol-defined Inclusion Criteria apply
1. Pacientes con HPN que han completado, sin interrupción permanente, el tratamiento del estudio en al menos uno de los estudios de origen (R3918-PNH-2021 o R3918-PNH-2022), incluido el periodo de transición, si corresponde.

Se aplican otros criterios de inclusión definidos en el protocolo.
E.4Principal exclusion criteria
1. Significant protocol deviation(s) in the parent study based on the investigator’s judgment and to the extent that these would (if continued) impact the study objectives and/or safety of the patient (eg, repetitive non-compliance with dosing by the patient).
2. Any new condition or worsening of an existing condition which, in the opinion of the investigator, would make the patient unsuitable for enrollment or could interfere with the patient participating in or completing the study.

Other protocol-defined Exclusion Criteria apply
1. Desviaciones significativas del protocolo en el estudio de origen según la opinión del investigador y en la medida en que (si continuaran) afectarían los objetivos del estudio y/o la seguridad del paciente (por ejemplo, incumplimiento repetitivo de la administración del medicamento por parte del paciente).
2. Cualquier enfermedad nueva o empeoramiento de una enfermedad existente que, en opinión del investigador, haga que el paciente no sea adecuado para participar o pueda interferir con la capacidad del paciente para participar o finalizar el estudio.

Se aplican otros criterios de inclusión definidos en el protocolo.
E.5 End points
E.5.1Primary end point(s)
1. Incidence and severity of treatment-emergent serious adverse events (SAEs)
2. Incidence and severity of treatment-emergent adverse events of special interest (AESIs)
3. Treatment emergent adverse events (AEs) leading to permanent treatment discontinuation
4. Maintenance of adequate control of hemolysis
1. Incidencia y la gravedad de los acontecimientos adversos graves (AAG) surgidos durante el tratamiento
2. Incidencia y la gravedad de los acontecimientos adversos de interés especial (AAIE)
3. Incidencia y la gravedad de los AA que lleven a la suspensión permanente del tratamiento durante el periodo de extensión abierto de 108 semanas
4. Mantenimiento de un control adecuado de la hemólisis
E.5.1.1Timepoint(s) of evaluation of this end point
1-3: Up to week 108
4: Post-baseline to week 36
1-3: Hasta la semana 108
4: Post-basal hasta semana 36
E.5.2Secondary end point(s)
1. Maintenance of adequate control of hemolysis
2. Adequate control of hemolysis
3. Transfusion avoidance
4. Breakthrough hemolysis
5. Hemoglobin stabilization
6. Percent change in lactate dehydrogenase (LDH)
7. Change in fatigue as measured by the FACIT-Fatigue scale
8. Change in physical function (PF) scores on the EORTC QLQ-C30
9. Change in GHS/quality of life (QOL) scale on the EORTC QLQ-C30
10. Normalization of LDH
11. Rate of RBC transfusion
12. Number of units of RBC transfusion
13. Percentage of days with LDH ≤1.5x upper limit of normal (ULN)
14. Change in hemoglobin levels
15. Change in CH50
16. Percent change in CH50
17. Concentrations of total pozelimab in serum
18. Concentrations of cemdisiran in plasma
19. Incidence of treatment-emergent anti-drug antibodies to pozelimab
20. Incidence of treatment-emergent anti-drug antibodies to cemdisiran
21. Concentration of total C5 in plasma
22. Percent change of concentration of total C5 in plasma
• Mantenimiento de un control adecuado de la hemólisis
• Control adecuado de la hemólisis
• Evitación de transfusiones,
• Hemólisis irruptiva
• Estabilización de la hemoglobina
• Cambio porcentual en la LDH
• Variaciones en el grado de fatiga medidas a través de la escala FACIT-fatiga
• Cambios en las puntuaciones de la función física (FF) en los ítems EORTC QLQ-C30
• Cambio en la escala ESG/CV (calidad de vida) en el EORTC QLQ-C30
• Normalización de la cantidad de LDH,
• Porcentaje de transfusión de eritrocitos
• Número de unidades de transfusión de eritrocitos
• Porcentaje de días con la LDH ≤1,5 × LSN desde el momento basal
• Cambio en la cantidad de hemoglobina
• Cambio en CH50
• Cambio porcentual en CH50
• Concentraciones de pozelimab total en suero
• Concentraciones de cemdisiran en plasma
• Incidencia de anticuerpos contra el pozelimab surgidos durante el tratamiento
• Incidencia de anticuerpos contra el cemdisiran surgidos durante el tratamiento
• Concentración de C5 total en plasma
• Cambio en el porcentaje de concentración de C5 total en plasma
E.5.2.1Timepoint(s) of evaluation of this end point
1: Post-baseline through week 48, 76, 108
2, 10: Post-baseline through week 108
3-5, 11-13: Post-baseline through week 36, 48, 76, 108
6-9, 14: From baseline to week 36, 48, 76, 108
15-17, 19-22: Through week 108
18: Through week 24
1: Post-basal hasta el inicio de las semanas 48, 76, 108
2, 10: Post-basal hasta el inicio de la semana 108
3-5, 11-13: Post-basal hasta el inicio de las semanas 36, 48, 76, 108
6-9, 14: Desde semana basal hasta las semanas 36, 48, 76, 108
15-17, 19-22: hasta el inicio de la semana 108
18: hasta el inicio de la semana 24
E.6 and E.7 Scope of the trial
E.6Scope of the trial
E.6.1Diagnosis No
E.6.2Prophylaxis No
E.6.3Therapy Yes
E.6.4Safety Yes
E.6.5Efficacy Yes
E.6.6Pharmacokinetic Yes
E.6.7Pharmacodynamic Yes
E.6.8Bioequivalence No
E.6.9Dose response No
E.6.10Pharmacogenetic No
E.6.11Pharmacogenomic No
E.6.12Pharmacoeconomic No
E.6.13Others No
E.7Trial type and phase
E.7.1Human pharmacology (Phase I) No
E.7.1.1First administration to humans No
E.7.1.2Bioequivalence study No
E.7.1.3Other No
E.7.1.3.1Other trial type description
E.7.2Therapeutic exploratory (Phase II) No
E.7.3Therapeutic confirmatory (Phase III) Yes
E.7.4Therapeutic use (Phase IV) No
E.8 Design of the trial
E.8.1Controlled No
E.8.1.1Randomised No
E.8.1.2Open Yes
E.8.1.3Single blind No
E.8.1.4Double blind No
E.8.1.5Parallel group No
E.8.1.6Cross over No
E.8.1.7Other No
E.8.2 Comparator of controlled trial
E.8.2.1Other medicinal product(s) No
E.8.2.2Placebo No
E.8.2.3Other No
E.8.2.4Number of treatment arms in the trial1
E.8.3 The trial involves single site in the Member State concerned No
E.8.4 The trial involves multiple sites in the Member State concerned Yes
E.8.4.1Number of sites anticipated in Member State concerned2
E.8.5The trial involves multiple Member States Yes
E.8.5.1Number of sites anticipated in the EEA19
E.8.6 Trial involving sites outside the EEA
E.8.6.1Trial being conducted both within and outside the EEA Yes
E.8.6.2Trial being conducted completely outside of the EEA No
E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
Brazil
Canada
China
Colombia
France
Germany
Greece
Hungary
India
Italy
Japan
Jordan
Korea, Democratic People's Republic of
Malaysia
Mexico
Peru
Philippines
Poland
Romania
Singapore
South Africa
Spain
Taiwan
Thailand
Turkey
United Kingdom
United States
E.8.7Trial has a data monitoring committee No
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
The end of study is defined as the date the last patient completes the last study visit, withdraws from the study, or is lost to follow-up (ie, the study patient can no longer be contacted by the investigator)
El fin del estudio se define como la fecha en que el último paciente completa la última visita del estudio, se retira del estudio o se pierde durante el seguimiento (es decir, el investigador ya no puede ponerse en contacto con el paciente del estudio).
E.8.9 Initial estimate of the duration of the trial
E.8.9.1In the Member State concerned years5
E.8.9.1In the Member State concerned months2
E.8.9.1In the Member State concerned days
E.8.9.2In all countries concerned by the trial years5
E.8.9.2In all countries concerned by the trial months2
F. Population of Trial Subjects
F.1 Age Range
F.1.1Trial has subjects under 18 No
F.1.1.1In Utero No
F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
F.1.1.3Newborns (0-27 days) No
F.1.1.4Infants and toddlers (28 days-23 months) No
F.1.1.5Children (2-11years) No
F.1.1.6Adolescents (12-17 years) No
F.1.2Adults (18-64 years) Yes
F.1.2.1Number of subjects for this age range: 242
F.1.3Elderly (>=65 years) Yes
F.1.3.1Number of subjects for this age range: 46
F.2 Gender
F.2.1Female Yes
F.2.2Male Yes
F.3 Group of trial subjects
F.3.1Healthy volunteers No
F.3.2Patients Yes
F.3.3Specific vulnerable populations Yes
F.3.3.1Women of childbearing potential not using contraception No
F.3.3.2Women of child-bearing potential using contraception Yes
F.3.3.3Pregnant women No
F.3.3.4Nursing women No
F.3.3.5Emergency situation No
F.3.3.6Subjects incapable of giving consent personally No
F.3.3.7Others No
F.4 Planned number of subjects to be included
F.4.1In the member state2
F.4.2 For a multinational trial
F.4.2.1In the EEA 67
F.4.2.2In the whole clinical trial 288
F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
None
No
G. Investigator Networks to be involved in the Trial
N. Review by the Competent Authority or Ethics Committee in the country concerned
N.Competent Authority Decision Authorised
N.Date of Competent Authority Decision2023-01-09
N.Ethics Committee Opinion of the trial applicationFavourable
N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
N.Date of Ethics Committee Opinion2022-12-19
P. End of Trial
P.End of Trial StatusOngoing
3